Peter Leonardi, Ph.D., MBA – Founder and CEO of OmniCyte. Dr. Leonardi’s previous positions include: CFO of Protein Sciences (a private biotech company which received FDA approval for the first and only US approved recombinant seasonal influenza vaccine and grew from 45 employees to more than 100 during Peter's tenure, acquired by Sanofi for $750M), Director at Five Prime Advisors (a boutique Biotech Investment Bank), VP of Channel Development at ProCure Treatment Centers (a VC backed healthcare company), NY Presbyterian Hospital (University hospital of Cornell and Columbia Universities) where he led the office of technology transfer and served on the Columbia IRB 2003 to 2008. Dr Leonardi served on the National Cancer Institute Biotherapeutics SBIR study section from 2016 to 2022. Dr Leonardi has a Ph.D. from NYU Medical School and an MBA from Carnegie Mellon University.